PharMerica Reports Results for the First Quarter of 2013
PharMerica Reports Results for the First Quarter of 2013
Company Achieves Record Adjusted Diluted Earnings Per Share of $0.46
Company Achieves Record Adjusted EBITDA of $34.6 Million
Company Achieves Record Adjusted EBITDA Margin of 7.9%
Company Maintains Industry Leading Generic Dispensing Rate of 83.3%
Company Maintains 2013 Earnings Guidance
LOUISVILLE, Ky.--(BUSINESS WIRE)-- PharMerica Corporation (NYS: PMC) , a national provider of pharmacy services, today reported its financial results for the first quarter of 2013.
Commenting on the Company's results, Greg Weishar, PharMerica Corporation's Chief Executive Officer, said, "This quarter's results demonstrate the success of ongoing efforts to improve operations and profitability. The Company achieved record quarterly pharmacy gross margin and Adjusted EBITDA margin of 19.2% and 7.9%, respectively. On a sequential-quarter basis these margins increased 170 and 120 basis points, respectively. Adjusted diluted earnings per share increased 39% as compared to first quarter of 2012, and increased 28% on a sequential-quarter basis.
"We continue to see improvements in core pharmacy operations, which we believe will propel client retention and sales. I'm confident we are making progress towards achieving sustainable organic growth.
"Cash flow for the quarter was also strong, increasing from $19.9 million in the first quarter of 2012 to $47.7 million, primarily due to improved earnings and a lower investment in net working capital.
"Amerita, the specialty home infusion company that we acquired in fourth quarter 2012, saw solid growth and was accretive in the first quarter. We expect Amerita to be accretive for the balance of the year. Last month, we repaid the full amount borrowed to acquire Amerita using cash generated from operations.
"Finally, we are reaffirming 2013 guidance and expect to deliver strong financial and operational performance throughout the remainder of the year."
The results for the first quarter are set forth below:
Key Comparisons of First Quarters Ended March 31, 2013 and 2012:
Net income for the first quarter of 2013 was $10.5 million, or $0.35 diluted earnings per share, compared with $5.6 million, or $0.19 diluted earnings per share, for the same period in 2012. Adjusted diluted earnings per share were $0.46 in 2013 compared with $0.33 adjusted diluted earnings per share in 2012, an increase of 39.4%.
Adjusted EBITDA for the first quarter of 2013 was $34.6 million compared with $26.8 million in the first quarter of 2012, an increase of 29.1%.
Gross profit for the first quarter of 2013 was $84.3 million compared with $72.6 million in the first quarter of 2012. Gross margin expanded 460 basis points to 19.2% in the first quarter of 2013 compared with 14.6% in the first quarter of 2012. The increase in gross margin was a result of the effectiveness of the Company's purchasing strategies as well as improved purchasing terms and an increase in the generic dispensing rate to 83.3% from 80.9%.
Revenues for the first quarter of 2013 were $439.8 million compared with $498.9 million for the first quarter of 2012, a decrease of 11.8%, driven in part by higher generic dispensing.
Cash flows provided by operating activities for the first quarter of 2013 were $47.7 million compared with cash flows provided by operating activities of $19.9 million in the first quarter of 2012, an increase of 139.7%. The increase in cash provided by operating activities was in large part due to a planned reduction in inventories combined with an improvement in accounts receivable collections.
The Company also announced that it is maintaining its 2013 guidance issued on February 7, 2013.
Conference Call
Management will hold a conference call to review the financial results for the first quarter on May 2, 2013, at 10:00 a.m. Eastern Time. To access the live webcast, visit the Investor Relations section of the Company's website at www.pharmerica.com or go to www.earnings.com. To access a telephonic replay of the call, which will be available one hour after the conclusion of the call through May 16, 2013, please dial 1-888-286-8010 (617-801-6888 if calling from outside the U.S.) and use passcode 85606921.
About PharMerica
PharMerica Corporation is a leading institutional pharmacy services company that services healthcare facilities in the United States, provides pharmacy management services to hospitals, and also provides specialty infusion services to patients outside a hospital setting. As of March 31, 2013, PharMerica operated 90 institutional pharmacies and 12 specialty infusion centers in 45 states. PharMerica's customers are institutional healthcare providers, such as skilled nursing facilities, nursing centers, assisted living facilities, hospitals, individuals receiving in-home care and other long-term alternative care providers.
Forward-looking Statements
This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which reflect the Company's current estimates, expectations and projections about its future results, performance, prospects and opportunities.Forward-looking statements include, among other matters, the information concerning the Company's "guidance" and possible future results of operations, the strength of the Company's financial and operational performance during 2013, the impact of the brand to generic drug conversions on the Company, the Company's ability to identify and consummate future acquisitions, the Company's ability to deliver outstanding value to its shareholders, the Company's continued pursuit of its strategic initiatives including those focused on client retention and operating margins, the Company's ability to grow the Amerita specialty infusion business, and the Company's ability to achieve organic growth.Forward-looking statements include statements that are not historical facts and can be identified by forward-looking words such as "anticipate," "believe," "could," "estimate," "expect," "intend," "plan," "may," "should," "will," "would," "project" and similar expressions.These forward-looking statements are based upon information currently available to us and are subject to a number of risks, uncertainties and other factors that could cause the Company's actual results, performance, prospects or opportunities to differ materially from those expressed in, or implied by, these forward-looking statements.Important factors that could cause the Company's actual results to differ materially from the results referred to in the forward-looking statements we make in this press release are included in the Risk Factors section set forth in the Company's Annual Report on Form 10-K filed with the SEC and in other reports, including Quarterly Reports on Form 10-Q filed with the SEC by the Company.
You are cautioned not to place undue reliance on any forward-looking statements, all of which speak only as of the date of this press release.Except as required by law, we undertake no obligation to publicly update or release any revisions to these forward-looking statements to reflect any events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events.All subsequent written and oral forward-looking statements attributable to us or any person acting on the Company's behalf are expressly qualified in their entirety by the cautionary statements contained or referred to in this press release and in the Risk Factors section set forth in the Company's Annual Report on Form 10-K filed with the SEC and in other reports filed with the SEC by the Company.
PHARMERICA CORPORATION UNAUDITED CONDENSED CONSOLIDATED INCOME STATEMENTS (In millions, except share and per share amounts) | |||||||||||||||||
Three Months Ended | |||||||||||||||||
2012 | 2013 | ||||||||||||||||
Amount | % of | Amount | % of | ||||||||||||||
Revenues | $ | 498.9 | 100.0 | % | $ | 439.8 | 100.0 | % | |||||||||
Cost of goods sold | 426.3 | 85.4 | 355.5 | 80.8 | |||||||||||||
Gross profit | 72.6 | 14.6 | 84.3 | 19.2 | |||||||||||||
Selling, general and administrative expenses | 52.4 | 10.5 | 56.7 | 12.9 | |||||||||||||
Amortization expense | 2.8 | 0.6 | 4.1 | 0.9 | |||||||||||||
Merger, acquisition, integration costs and other charges | 5.4 | 1.1 | 2.9 | 0.7 | |||||||||||||
Hurricane Sandy disaster costs | - | - | 0.6 | 0.1 | |||||||||||||
Operating income | 12.0 | 2.4 | 20.0 | 4.6 | |||||||||||||
Interest expense, net | 2.7 | 0.5 | 2.6 | 0.6 | |||||||||||||
Income before income taxes | 9.3 | 1.9 | 17.4 | 4.0 | |||||||||||||
Provision for income taxes | 3.7 | 0.8 | 6.9 | 1.6 | |||||||||||||
Net income | $ | 5.6 | 1.1 | % | $ | 10.5 | 2.4 | % | |||||||||
Three Months Ended | |||||||||||||||||
2012 | 2013 | ||||||||||||||||
Earnings per common share: | |||||||||||||||||
Basic | $ | 0.19 | $ | 0.36 | |||||||||||||
Diluted | $ | 0.19 | $ | 0.35 | |||||||||||||
Shares used in computing earnings per common share: | |||||||||||||||||
Basic | 29,430,190 | 29,566,959 | |||||||||||||||
Diluted | 29,710,150 | 30,063,737 | |||||||||||||||
PHARMERICA CORPORATION UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS (In millions, except share and per share amounts) | ||||||||||
(As Adjusted) | ||||||||||
Dec. 31, | March 31, | |||||||||
ASSETS | ||||||||||
Current assets: | ||||||||||
Cash and cash equivalents | $ | 12.3 | $ | 7.8 | ||||||
Accounts receivable, net | 206.6 | 207.7 | ||||||||
Inventory | 135.7 | 100.2 | ||||||||
Deferred tax assets, net | 36.7 | 33.2 | ||||||||
Prepaids and other assets | 38.8 | 37.5 | ||||||||
430.1 | 386.4 | |||||||||
Equipment and leasehold improvements | 158.8 | 163.2 | ||||||||
Accumulated depreciation | (105.7 | ) | (108.3 | ) | ||||||
53.1 | 54.9 | |||||||||
Goodwill | 268.5 | 268.5 | ||||||||
Intangible assets, net | 121.9 | 120.1 | ||||||||
Other | 12.7 | 11.0 | ||||||||
$ | 886.3 | $ | 840.9 | |||||||
LIABILITIES AND STOCKHOLDERS' EQUITY | ||||||||||
Current liabilities: | ||||||||||
Accounts payable | $ | 49.7 | $ | 36.8 | ||||||
Salaries, wages and other compensation | 35.8 | 33.4 | ||||||||
Current portion of long-term debt | 12.5 | 12.5 | ||||||||
Other accrued liabilities | 9.1 | 10.8 | ||||||||
107.1 | 93.5 | |||||||||
Long-term debt | 303.0 | 259.2 | ||||||||
Other long-term liabilities | 22.5 | 23.4 | ||||||||
Deferred tax liabilities | 11.1 | 11.2 | ||||||||
Commitments and contingencies | ||||||||||
Stockholders' equity: | ||||||||||
Preferred stock, $0.01 par value per share; 1,000,000 shares authorized and no shares issued at December 31, 2012 and March 31, 2013 | - | - | ||||||||
Common stock, $0.01 par value per share; 175,000,000 shares authorized; 30,943,748 and 31,270,088 shares issued as of December 31, 2012 and March 31, 2013, respectively | 0.3 | 0.3 | ||||||||
Capital in excess of par value | 363.0 | 365.3 | ||||||||
Retained earnings | 91.3 | 101.8 | ||||||||
Treasury stock at cost, 1,456,293 shares and 1,574,782 shares at December 31, 2012 and March 31, 2013, respectively | (12.0 | ) | (13.8 | ) | ||||||
442.6 | 453.6 | |||||||||
$ | 886.3 | $ | 840.9 | |||||||
PHARMERICA CORPORATION UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (In millions) | ||||||||||
Three Months Ended | ||||||||||
2012 | 2013 | |||||||||
Cash flows provided by (used in) operating activities: | ||||||||||
Net income | $ | 5.6 | $ | 10.5 | ||||||
Adjustments to reconcile net income to net cash provided by (used in) operating activities: | ||||||||||
Depreciation | 4.8 | 4.8 | ||||||||
Amortization | 2.8 | 4.1 | ||||||||
Merger, acquisition integration costs and other charges | 1.6 | - | ||||||||
Hurricane Sandy disaster costs | - | (0.6 | ) | |||||||
Stock-based compensation and deferred compensation | 1.8 | 2.2 | ||||||||
Amortization of deferred financing fees | 0.2 | 0.3 | ||||||||
Deferred income taxes | 2.6 | 3.6 | ||||||||
Gain on disposition of equipment | (0.1 | ) | - | |||||||
Other | (0.2 | ) | 0.1 | |||||||
Change in operating assets and liabilities: | ||||||||||
Accounts receivable, net | (12.1 | ) | (1.2 | ) | ||||||
Inventory | 26.5 | 35.5 | ||||||||
Prepaids and other assets | (0.5 | ) | 3.4 | |||||||
Accounts payable | (7.0 | ) | (12.6 | ) | ||||||
Salaries, wages and other compensation | (6.5 | ) | (4.8 | ) | ||||||
Other accrued liabilities | 0.4 | 2.4 | ||||||||
Net cash provided by operating activities | 19.9 | 47.7 | ||||||||
Cash flows provided by (used in) investing activities: | ||||||||||
Purchase of equipment and leasehold improvements | (2.5 | ) | (6.7 | ) | ||||||
Acquisitions, net of cash acquired | - | (0.5 | ) | |||||||
Cash proceeds from the sale of assets | 0.1 | - | ||||||||
Net cash used in investing activities | (2.4 | ) | (7.2 | ) | ||||||
Cash flows provided by (used in) financing activities: | ||||||||||
Repayments of long-term debt | - | (3.1 | ) | |||||||
Net activity of long-term revolving credit facility | (27.9 | ) | (40.5 | ) | ||||||
Repayments of capital lease obligations | (0.1 | ) | - | |||||||
Issuance of common stock | - | 0.1 | ||||||||
Treasury stock at cost | (0.2 | ) | (1.8 | |||||||
